1088 related articles for article (PubMed ID: 11279727)
61. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
Chu LW; Yik PY; Mok W; Chung CP
Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
[TBL] [Abstract][Full Text] [Related]
62. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
Farina N; Llewellyn D; Isaac MGEKN; Tabet N
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002854. PubMed ID: 28418065
[TBL] [Abstract][Full Text] [Related]
63. Nimodipine for primary degenerative, mixed and vascular dementia.
López-Arrieta JM; Birks J
Cochrane Database Syst Rev; 2002; (3):CD000147. PubMed ID: 12137606
[TBL] [Abstract][Full Text] [Related]
64. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.
Raskind MA; Peskind ER; Wessel T; Yuan W
Neurology; 2000 Jun; 54(12):2261-8. PubMed ID: 10881250
[TBL] [Abstract][Full Text] [Related]
65. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.
Kaduszkiewicz H; Zimmermann T; Beck-Bornholdt HP; van den Bussche H
BMJ; 2005 Aug; 331(7512):321-7. PubMed ID: 16081444
[TBL] [Abstract][Full Text] [Related]
66. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease.
Wilkinson D; Murray J
Int J Geriatr Psychiatry; 2001 Sep; 16(9):852-7. PubMed ID: 11571763
[TBL] [Abstract][Full Text] [Related]
67. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
Rockwood K; Dai D; Mitnitski A
Int J Geriatr Psychiatry; 2008 Feb; 23(2):207-14. PubMed ID: 17621382
[TBL] [Abstract][Full Text] [Related]
68. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Atri A; Frölich L; Ballard C; Tariot PN; Molinuevo JL; Boneva N; Windfeld K; Raket LL; Cummings JL
JAMA; 2018 Jan; 319(2):130-142. PubMed ID: 29318278
[TBL] [Abstract][Full Text] [Related]
69. Piracetam for dementia or cognitive impairment.
Flicker L; Grimley Evans G
Cochrane Database Syst Rev; 2001; (2):CD001011. PubMed ID: 11405971
[TBL] [Abstract][Full Text] [Related]
70. Memantine for dementia.
Areosa SA; Sherriff F; McShane R
Cochrane Database Syst Rev; 2005 Apr; (2):CD003154. PubMed ID: 15846650
[TBL] [Abstract][Full Text] [Related]
71. Effects of galantamine in patients with mild Alzheimer's disease.
Orgogozo JM; Small GW; Hammond G; Van Baelen B; Schwalen S
Curr Med Res Opin; 2004 Nov; 20(11):1815-20. PubMed ID: 15537482
[TBL] [Abstract][Full Text] [Related]
72. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
[TBL] [Abstract][Full Text] [Related]
73. Galantamine treatment in outpatients with mild Alzheimer's disease.
Richarz U; Gaudig M; Rettig K; Schauble B
Acta Neurol Scand; 2014 Jun; 129(6):382-92. PubMed ID: 24461047
[TBL] [Abstract][Full Text] [Related]
74. Nimodipine for primary degenerative, mixed and vascular dementia.
López-Arrieta ; Birks J
Cochrane Database Syst Rev; 2001; (1):CD000147. PubMed ID: 11279679
[TBL] [Abstract][Full Text] [Related]
75. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis.
Trinh NH; Hoblyn J; Mohanty S; Yaffe K
JAMA; 2003 Jan; 289(2):210-6. PubMed ID: 12517232
[TBL] [Abstract][Full Text] [Related]
76. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.
Tariot PN; Solomon PR; Morris JC; Kershaw P; Lilienfeld S; Ding C
Neurology; 2000 Jun; 54(12):2269-76. PubMed ID: 10881251
[TBL] [Abstract][Full Text] [Related]
77. Donepezil for mild cognitive impairment.
Birks J; Flicker L
Cochrane Database Syst Rev; 2006 Jul; (3):CD006104. PubMed ID: 16856114
[TBL] [Abstract][Full Text] [Related]
78. The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis.
Kobayashi H; Ohnishi T; Nakagawa R; Yoshizawa K
Int J Geriatr Psychiatry; 2016 Aug; 31(8):892-904. PubMed ID: 26680338
[TBL] [Abstract][Full Text] [Related]
79. Memantine for dementia.
Areosa SA; Sherriff F; McShane R
Cochrane Database Syst Rev; 2005 Jul; (3):CD003154. PubMed ID: 16034889
[TBL] [Abstract][Full Text] [Related]
80. Carotid intima-media thickness as a predictor of response to cholinesterase inhibitors in Alzheimer's disease: an open-label trial.
Modrego PJ; Rios C; Pérez Trullen JM; García-Gómara MJ; Errea JM
CNS Drugs; 2009; 23(3):253-60. PubMed ID: 19320533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
